Literature DB >> 26367273

NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria.

Massimo Bertinaria1, Pamela Orjuela-Sanchez2, Elisabetta Marini1, Stefano Guglielmo1, Anthony Hofer2, Yuri C Martins2, Graziela M Zanini3, John A Frangos2, Alberto Gasco1, Roberta Fruttero1, Leonardo J M Carvalho4.   

Abstract

Hybrid products in which the dihydroartemisinin scaffold is combined with NO-donor furoxan and NONOate moieties have been synthesized and studied as potential tools for the treatment of cerebral malaria (CM). The designed products were able to dilate rat aorta strips precontracted with phenylephrine with a NO-dependent mechanism. All hybrid compounds showed preserved antiplasmodial activity in vitro and in vivo against Plasmodium berghei ANKA, comparable to artesunate and artemether. Hybrid 10, selected for additional studies, was capable of increasing survival of mice with late-stage CM from 27.5% to 51.6% compared with artemether. Artemisinin-NO-donor hybrid compounds show promise as potential new drugs for treating cerebral malaria.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26367273      PMCID： PMC6003618          DOI： 10.1021/acs.jmedchem.5b01036

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  20 in total

Review 1.  Diagnosis and management of the neurological complications of falciparum malaria.

Authors:  Saroj K Mishra; Charles R J C Newton
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

2.  Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology.

Authors:  Pedro Cabrales; Graziela M Zanini; Diana Meays; John A Frangos; Leonardo J M Carvalho
Journal:  J Infect Dis       Date:  2011-03-16       Impact factor: 5.226

3.  Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain.

Authors:  L Clemmer; Y C Martins; G M Zanini; J A Frangos; L J M Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

4.  Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria.

Authors:  Massimo Bertinaria; Stefano Guglielmo; Barbara Rolando; Marta Giorgis; Cristina Aragno; Roberta Fruttero; Alberto Gasco; Silvia Parapini; Donatella Taramelli; Yuri C Martins; Leonardo J M Carvalho
Journal:  Eur J Med Chem       Date:  2011-02-22       Impact factor: 6.514

Review 5.  Malaria biology and disease pathogenesis: insights for new treatments.

Authors:  Louis H Miller; Hans C Ackerman; Xin-zhuan Su; Thomas E Wellems
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

6.  Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome.

Authors:  Tsin W Yeo; Daniel A Lampah; Emiliana Tjitra; Retno Gitawati; Christabelle J Darcy; Catherine Jones; Enny Kenangalem; Yvette R McNeil; Donald L Granger; Bert K Lopansri; J Brice Weinberg; Ric N Price; Stephen B Duffull; David S Celermajer; Nicholas M Anstey
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

7.  Transdermal glyceryl trinitrate as an effective adjunctive treatment with artemether for late-stage experimental cerebral malaria.

Authors:  Pamela Orjuela-Sánchez; Peng Kai Ong; Graziela M Zanini; Benoît Melchior; Yuri C Martins; Diana Meays; John A Frangos; Leonardo J M Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

8.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Authors:  Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White
Journal:  Lancet       Date:  2010-11-07       Impact factor: 79.321

9.  A lactate dehydrogenase ELISA-based assay for the in vitro determination of Plasmodium berghei sensitivity to anti-malarial drugs.

Authors:  Pamela Orjuela-Sánchez; Erika Duggan; John Nolan; John A Frangos; Leonardo Jm Carvalho
Journal:  Malar J       Date:  2012-11-05       Impact factor: 2.979

10.  Nitric oxide synthase dysfunction contributes to impaired cerebroarteriolar reactivity in experimental cerebral malaria.

Authors:  Peng Kai Ong; Benoît Melchior; Yuri C Martins; Anthony Hofer; Pamela Orjuela-Sánchez; Pedro Cabrales; Graziela M Zanini; John A Frangos; Leonardo J M Carvalho
Journal:  PLoS Pathog       Date:  2013-06-20       Impact factor: 6.823
View more
  2 in total

Review 1.  Are Antimalarial Hybrid Molecules a Close Reality or a Distant Dream?

Authors:  Drishti Agarwal; Rinkoo D Gupta; Satish K Awasthi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  Pathophysiological Mechanisms in Gaseous Therapies for Severe Malaria.

Authors:  Ana Carolina A V Kayano; João Conrado K Dos-Santos; Marcele F Bastos; Leonardo J Carvalho; Júlio Aliberti; Fabio T M Costa
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.